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Aiqing Li, Yongjie Wang* and Zheng DengAbstract
Background: Both autoimmune pancreatitis (AIP) and primary biliary cirrhosis (PBC) are related to various diseases.
But the concurrence of AIP and PBC is extremely rare, with only 2 cases reported. Here we report the concurrence
of AIP and PBC in a Chinese patient for the first time.
Case presentation: A 65-year-old male was admitted to our hospital with jaundice, pruritus, mild abdominal
pain and darkening urine. Serum alkaline phosphatase, γ-glutamyltransferase, bilirubin and IgG4 were prominently
elevated. The antimitochondrial antibody was positive. Radiological examination revealed diffusive enlargement
of the pancreas. Pancreatic biopsy showed lymphoplasmacytic infiltration, fibrosis and abundant IgG4+ plasma
cells. The patient was diagnosed with AIP and PBC. Nasobiliary tube was placed to facilitate biliary drainage. A
combination therapy of steroid and UDCA was administered and the patient was gradually recovered, during
which the patient was complicated with biliary infecion, herpes zoster and pulmonary abscess.
Conclusion: We present this case together with literature evidence to support the concurrence of AIP and PBC,
share our experience of using combination therapy with steroid and UDCA, and raise the awareness of infectious
complications in immunosuppressed patients.
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The term autoimmune pancreatitis (AIP) defines a group
of pancreatitis characterized by obstructive jaundice,
lymphoplasmacytic infiltration and fibrosis and dramatic
steroid response [1]. AIP has been divided into two dis-
tinct forms, in which type I is more common in Asia
and more closely related to immunoglobulin G4 (IgG4)
[2,3]. Recently type I AIP has been recognized as the
pancreatic manifestation of a multiorgan disorder named
as IgG4-related disease [2,4].
Primary biliary cirrhosis (PBC) is an autoimmune,
cholestatic liver disease that affects predominantly
middle-aged women and follows a slow-progressive
clinical course [5-7]. Its incidence is estimated to be be-
tween 0.7 and 49 cases per million-population per year
[8]. Histologically, PBC is characterized by immune-* Correspondence: 11018196@zju.edu.cn
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stated.mediated destruction of small and medium intrahepatic
bile ducts, which, if left untreated, will finally lead to bil-
iary cirrhosis [5-7].
Although both AIP and PBC are related to various dis-
eases [8,9], their concurrence in one patient is extremely
rare. Only two cases have been reported in association
with sclerosing cholangitis (SC) [10,11]. Here we report
a Chinese patient suffering from both AIP and PBC,
complicated with various infections and treated effect-
ively with ursodeoxycholic acid (UDCA) and steroid.
Case presentation
A 65-year-old male was admitted to our hospital com-
plaining of jaundice, pruritus, mild right upper abdom-
inal pain and darkening urine. Past medical history
revealed atrial fibrillation and the patient was on inter-
mittent aspirin therapy. And the family history was
negative. Physical examination revealed icteric sclera and
skin, mild upper abdominal tenderness, arythmia, irregu-
lar heart sound and pulse deficit.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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the serum levels of alanine transaminase (ALT), aspar-
tate transaminase (AST), alkaline phosphatase (ALP),
γ-glutamyltransferase (γ-GT), total bilirubin (TBil) and
direct bilirubin (DBil) were elevated to 79 U/L (5-45 U/L),
51 U/L (5-35 U/L), 540 U/L (30-110 U/L), 197 U/L (7-50
U/L), 408 μmol/L(0-20.5 μmol/L) and 283.7 μmol/L (0-6.8
μmol/L), respectively. Serum IgG and IgM were 3,180
mg/dL (694-1620 mg/dL) and 344 mg/dL (60-263 mg/dL),
respectively. The titer of antinuclear antibody (ANA) was
1:320. Screening for antoimmune diseases revealed that
the patient was positive for antimitochondrial antibody
(AMA), anti-AMA-M2 and anti-Ro antibody. Common
tumor markers and viral markers were all negative.
Both computed tomography (CT) and magnetic reson-
ance image (MRI) revealed diffusive enlargement of the
pancreas, capsuled by an armorlike low-density rim and
enhanced homogenously (Figure 1). Other abnormalities
included significant dilation of intra- and extra-hepatic
bile duct, diffusive thickening of the gallbladder wall and
atrophy of the right kidney. Endoscopic retrograde
cholangio-pancreatography (ERCP) was conducted, re-
vealing similar findings with CT and MRI. No sign of
malignancy was observed. Test of tumor markers from
the bile showed CEA of 66.89 ng/mL (0-5 ng/mL) andFigure 1 CT and MRI scan of the patient. Uncontract CT image (A), T1 w
enlargement of the pancreas capsuled by an armorlike rim, significant dilat
the right kidney. Contrast CT (B: arterial phase; C: venous phase) and MRI (F
ing of the gallbladder wall. Repeat MRI (G) after effective treatment showe
Chest CT (H) showed a large patchy shadow in the right lower lobe. Repea
the lesion.CA199 larger than 4000 U/mL (<37.0 U/mL), but exami-
nations of exfoliated cells proved negative for three
consecutive times. The biliary culture was positive for
ESBL-producing Klebsiella pneumoniae. Infection was
suspected and meropenem (0.5 g per 8 hours) was
administered.
Based on the biochemical evidence of cholestasis from
the elevation of ALP, γ-GT and TBil, and the presence of
AMA, the patient was clinically diagnosed with PBC and
UDCA (250 mg, three times per day) was initiated im-
mediately after nasobiliary drainage [12], which partially
improved the patient’s liver function (Figure 2). Since the
patient was also suspected of suffering from AIP, the fol-
lowing examinations were conducted. IgG4 was measured
and turned out to be 44.36 g/L (0.03-2 g/L). CT-guided
pancreatic biopsy was performed, and histopathological
evaluation showed dense lymphoplasmacytic infiltration
and fibrosis. IgG4+ plasma cell was stained and counted
to be as high as 95 per high-power field (HPF) (Figure 3).
ECT of salivary gland was normal. So the diagnosis of
type I AIP was confirmed in accordance with the diagnos-
tic criteria [1].
Steroid therapy with intravenous methylprednisolone
(MEP) (40 mg per day) was administered promptly.
Serum ALP, γ-GP, TBil and DBil just before steroideighted image (D) and T2 weighted image (E) displayed diffusive
ion of intra- and extra-heptic bile duct and gallbladder, and atrophy of
) revealed homogeneously enhanced pancreas and diffusive thicken-
d remarkable reduction of the pancreas, gallbadder and bile ducts.
t CT (I) after antibiotic treatment showed remarkable absorption of
Figure 2 Clinical course of liver enzymes and bilirubin during
combination therapy with ursodeoxycholic acid (UDCA) and
methylprednisolone (MEP).
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μmol/L, respectively, and one week later were 243 U/L,
47 U/L, 47 U/L, 206.1 μmol/L and 167.1 μmol/L, re-
spectively. Then we stepped down the steroid therapy
with oral MEP 32 mg daily, yet the serum liver enzymes
and bilirubin bounced up. So we increased the dose to
32 mg in the morning and 16 mg in the afternoon. And
then the laboratory values improved. A repeat MRI
showed remarkable reduction of the pancreas. 40 days
after treatment, the IgG and IgM returned back into the
normal range. The serum levels of ALP, γ-GP, TBil and
DBil were 135 U/L, 134 U/L, 82.8 μmol/L and 54.9
μmol/L, respectively. The patient was discharged and
followed up at the clinic with MEP tapered off weekly by
5 mg. The clinical course is depicted in Figure 2.
About 40 days after discharge, the patient developed
red maculopapules on his right chest with prickling-like
pain, worsened with erosion and blisters. The patient
was diagnosed with herpes zoster and treated with
acyclovir (500 mg twice a day) for 9 days. Unfortunately
for the patient, a chest X-ray later showed multipleFigure 3 Hematoxylin and eosin (HE) staining and immunohistochem
lymphoplasmacytic infiltration and fibrosis. IHC (B) showed abundant IgG4nodules in the right lung. Chest CT displayed multiple
patchy shadows with cavity. CT-guided lung biopsy
showed neutrophil aggregation and fibrous effusion
within the alveoli. The patient was diagnosed with pul-
monary abscess and was treated effectively with moxi-
floxacin (Figure 1). Given the immunosuppressed status
of the patient, thymosin was injected twice a week to
restore the immune function. The liver function and
immunological indices of the patient were normal dur-
ing the subsequent one-year follow-up period.
Discussion
2 types of AIP have been recognized. Type I AIP
commonly causes painless obstructive jaundice and fre-
quently features elevated serum IgG4 [2,13]. Lympho-
plasmacytic infiltration, storiform fibrosis, obliterative
phlebitis and abundant IgG4-positive cells (>10/HPF)
are the diagnostic histological changes [2,4]. In contrast,
type II is more often manifested as acute pancreatitis,
lacking abnormal immunological findings and some-
times associated with inflammatory bowel disease [2,13].
PBC is an autoimmune disease with uncleared etiology.
It is proposed that the mitochondrial enzymes are
presented to the the immune system, trigering autoanti-
body production and immune-mediated destruction
[6,8,12,14]. Patient often presents with fatigue, pruritus,
osteoporosis and hyperlipidemia [8,12,15]. Although AIP
and PBC are associated with other organ involvment
[8,9], their concurrence has been reported in only two
cases, one being treated with UDCA and steroid [11],
while the other with UDCA and stent dilation [10]. Here
we report the first Chinese patient diagnosed with PBC
and AIP who responded well to UDCA and steroid but
was complicated with infections.
There are varying diagnostic criteria for AIP world-
wide, thus making diagnosis a challenge [3]. Recently, a
universal guideline has been developed based on 5 car-
dinal features [1], namely, characteristic radiological
findings, elevated serum IgG4, other organ involvementistry (IHC) of the pancreatic tissue. HE stain (A, ×200) showed dense
+ plasma cell infiltration.
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creatic biopsy is not mandatory, but necessary for
patients with vague findings from CT, serology and OOI.
ERCP is reserved for patients whose biopsy is unfeasible
or inconclusive. Steroid trial can be considered only
when cancer is excluded [2]. Given the characteritic CT
and MRI features, markedly elevated IgG4 and histo-
pathological findings, the diagnosis of AIP in our case is
unambiguous.
The diagnosis of PBC is based on the biochemical
evidence of cholestasis, presence of AMA and histopath-
ology [12]. AMA is a highly disease-specific autoanti-
body found in 90%-95% of patients with PBC and fewer
than 1% of normal controls [12], and AMA (M2) is a
mitochondrial antigen specifically associated to PBC
[14]. Similar to AIP, biopsy is not nessasary in typical
cases unless AMA is negative [8,12]. In our case, the ab-
normal liver function could also be explained by AIP.
Unfortunately, a premorbid test of liver funciton was not
available. The patient also refused to undergo liver
biopsy. A lab test 2 months after initiation of steroid
therapy still showed mild cholestasis (ALP 166 U/L,
γ-GT 179 U/L, TBil 63.7 μmol/L, Dbil 37.6 μmol/L),
which were uncommon in AIP cases with effective
biliary drainage and dramatic radiological improvement
after steroid treatment. Moreover, after a thorough
literature searching, we failed to find any published
evidence of positive AMA in AIP. Therefore, we clinic-
ally diagnosed the patient with PBC.
Extrapancreatic lesions occur in most cases of type I
AIP and are positively correlated with serum IgG4 levels
[9,16,17]. The biliary system, salivary glands, thyroid,
lymph nodes, lung, retroperitoneum and kidney are
most frequently involved [3,18,19]. Biliary and gallblad-
der involvement is often manifested as diffusive wall
thickening [19,20]. Renal lesions are usually shown as
swelling and a nodular or an irregular pattern on CT
[3,21,22]. In our case, CT image demonstrated en-
hancement and wall thickening of the gallbladder and
common bile duct, which might be caused by ob-
struction due to the enlarged pancreas, or manifested
as the extrapancreatic involvement in AIP. However,
the right renal atrophy did not comply with the
characterisitic radiological findings of IgG4 related
renal lesion.
Given the systemic nature of AIP and PBC, it is tempt-
ing to think that the coexistence of AIP and PBC is not
a coincidence. A survey of the pathogenesis of both dis-
eases reveals several common features. 1. Genetic studies
discovered susceptibility to both AIP and PBC conferred
by HLA-DQB1 [23,24]; 2. dysregulation of cytotoxic
T-lymphocyte antigen-4 (CTLA-4) was found in AIP
and PBC [2,14]; 3. both AIP and PBC were most likely
to be T-cell mediated [2,14]; 4. circulating autoantibodiesand infiltration of plasma cells indicated an important
role of B cells in AIP and PBC [2,6,25,26].
Steroid is the treatment of first choce for AIP, whose
recommended starting dose is 0.6-1 mg/kg/day [1]. After
2-4 weeks, the dose is tapered by 5 mg every 1-2 weeks
until it reaches 5-10 mg/day [27]. As for PBC, UDCA at
a dose of 13-15 mg/kg/day is the only FDA-approved
therapy [7,8,12,14]. However, UDCA does not help to re-
lieve fatigue, pruritus, osteoporosis and concurrent auto-
immune disorders [12]. Liver transplantation is reserved
as the final option for end-stage liver failure [8,25].
There is limited experience in treating concurrent AIP
and PBC. The combination of UDCA and steroid seems
to be nessasary. Naitoh has shown that discontinuation
of UDCA resulted in the elevation of liver enzymes [11].
In our case, tapering steroid off too early led to the
rebounce of bilirubin levels.
In our case, the patient developed biliary infecion, her-
pes zoster and pulmonary abscess. Therefore, infectious
complications should be noted during treatment of AIP
and PBC. It was found that benign extrahepatic biliary
obstruction could promote bacterial translocation [28].
Obstruction relief and infection control are the keys to
preventing septic complications. Steroid use is also asso-
ciated with infections [29]. Herpes zoster and uncom-
mon pulmonary abscess have been reported [29-32].
Active immunization is recommended before applying
steroid in patients without varicella zoster virus vaccin-
ation [29]. Pulmonary abscess is mainly controlled with
antibiotics and postural drainage [33]. In our case, the
patient was controlled effectively with antiviral drugs
and antibiotics. Finally thymosin was administered to
ramp up the patient’s immune function.
Conclusion
In summary, we report an extremely rare Chinese case
of concurrent AIP and PBC. Unlike previous reported
cases, this patient’s clinical course was complicated by
various infectious complications. The purpose of pre-
senting this case is to provide insights into the concur-
rence of AIP and PBC, stress the importance of
combination therapy with steroid and UDCA, and raise
the awareness of infectious complications in immuno-
suppressed patients.
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